Keros Therapeutics does not distribute a dividend yield to its shareholders, as is typical for clinical-stage biopharmaceutical companies operating in the biotechnology sector. Because the firm is focused heavily on research, extensive preclinical studies, and costly multi-phase clinical trials for its therapeutic pipeline, it reinvests all available capital back into core operations rather than returning cash to investors via regular dividend payouts. Consequently, investors who purchase shares of the company typically look toward capital appreciation driven by clinical trial data readouts, regulatory approvals, and long-term commercialization milestones rather than income generation through dividends.